Christina Andreou1, Charlotte E Wittekind2, Martina Fieker2, Ulrike Heitz3, Ruth Veckenstedt2, Francesca Bohn2, Steffen Moritz2. 1. Center for Gender Research and Early Detection, University Psychiatric Clinics Basel, Switzerland; Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Christina.Andreou@upkbs.ch. 2. Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Germany. 3. Center for Gender Research and Early Detection, University Psychiatric Clinics Basel, Switzerland.
Abstract
BACKGROUND: Theory-driven interventions targeting specific factors that contribute to delusions are receiving increased interest. The present study aimed to assess the efficacy of individualized metacognitive therapy (MCT+), a short manualized intervention that addresses delusion-associated cognitive biases. METHODS:92 patients with current or past delusions were randomized to receive 12 twice-weekly sessions of either MCT+ or a control intervention within a randomized controlled rater-blind design. Psychopathology and cognitive biases were assessed at baseline, 6 weeks and 6 months. ANCOVAs adjusted for baseline scores were used to assess differences between groups regarding outcome variables. Both per-protocol and intention-to-treat analyses were conducted. RESULTS: At 6 weeks, there was a significant difference in favor of MCT+ regarding decrease in delusion severity and improvement of self-reflectiveness (medium effect size), and a trend-wise difference regarding probability thresholds to decision. These effects increased, when only patients attending a minimum of 4 therapy sessions were considered. Control group patients subsequently showed further improvement while patients in the MCT+ group remained stable, such that there were no differences between groups at the 6-month follow-up. LIMITATIONS: Lower attendance rates in the control group possibly leading to unequal therapeutic effort; lower baseline delusion severity in the MCT+ group. CONCLUSIONS: The result pattern suggests that MCT+ led to earlier improvement in delusions and cognitive biases compared to the control intervention. The absence of a long-term effect might reflect floor effects in the MCT+ group, but may also indicate the need for further measures to promote sustainability of MCT+ effects.
RCT Entities:
BACKGROUND: Theory-driven interventions targeting specific factors that contribute to delusions are receiving increased interest. The present study aimed to assess the efficacy of individualized metacognitive therapy (MCT+), a short manualized intervention that addresses delusion-associated cognitive biases. METHODS: 92 patients with current or past delusions were randomized to receive 12 twice-weekly sessions of either MCT+ or a control intervention within a randomized controlled rater-blind design. Psychopathology and cognitive biases were assessed at baseline, 6 weeks and 6 months. ANCOVAs adjusted for baseline scores were used to assess differences between groups regarding outcome variables. Both per-protocol and intention-to-treat analyses were conducted. RESULTS: At 6 weeks, there was a significant difference in favor of MCT+ regarding decrease in delusion severity and improvement of self-reflectiveness (medium effect size), and a trend-wise difference regarding probability thresholds to decision. These effects increased, when only patients attending a minimum of 4 therapy sessions were considered. Control group patients subsequently showed further improvement while patients in the MCT+ group remained stable, such that there were no differences between groups at the 6-month follow-up. LIMITATIONS: Lower attendance rates in the control group possibly leading to unequal therapeutic effort; lower baseline delusion severity in the MCT+ group. CONCLUSIONS: The result pattern suggests that MCT+ led to earlier improvement in delusions and cognitive biases compared to the control intervention. The absence of a long-term effect might reflect floor effects in the MCT+ group, but may also indicate the need for further measures to promote sustainability of MCT+ effects.
Authors: D J Hauke; V Roth; P Karvelis; R A Adams; S Moritz; S Borgwardt; A O Diaconescu; C Andreou Journal: Schizophr Bull Date: 2022-06-21 Impact factor: 7.348
Authors: Ellaheh Gohari; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey Journal: Psychiatry Res Date: 2022-02-25 Impact factor: 11.225
Authors: Steffen Moritz; Candelaria I Mahlke; Stefan Westermann; Friederike Ruppelt; Paul H Lysaker; Thomas Bock; Christina Andreou Journal: Schizophr Bull Date: 2018-02-15 Impact factor: 9.306
Authors: Philippa A Garety; Thomas Ward; Daniel Freeman; David Fowler; Richard Emsley; Graham Dunn; Elizabeth Kuipers; Paul Bebbington; Helen Waller; Kathryn Greenwood; Mar Rus-Calafell; Alison McGourty; Amy Hardy Journal: Trials Date: 2017-11-02 Impact factor: 2.279